Hormone Therapy News

The FDA approved a supplemental new drug application for the hormone-releasing intrauterine device Liletta 52 mg that extends the device’s duration for pregnancy prevention for a maximum of 6 years, according to a press release.

Opko Health and Pfizer announced positive top-line results this week for an investigational long-acting growth hormone injection, noting the therapy was safe and effective for prepubertal children with GH deficiency, according to a press release from the two companies.

Friday marks the 10th anniversary of World Menopause Day, established by the International Menopause Society to show support for women worldwide and recognize the challenges of menopausal symptoms and related conditions.

Longer endogenous estrogen exposure and use of hormone therapy are associated with higher cognitive status in late life, especially among older women when compared with younger women, according to findings published in Menopause.

Young adults born small for gestational age treated with long-term growth hormone therapy had stable renal function in the 5 years after stopping treatment, with an estimated glomerular filtration rate comparable to healthy controls and young adults with short stature who did not receive GH, according to findings published in Clinical Endocrinology.

Laser therapy is as effective and safe as vaginal estrogen for improving sexual and urinary functionality during menopause, according to findings from a randomized controlled trial.

Among Danish women with Turner syndrome, those prescribed hormone therapy were less likely to develop diabetes, sustain an osteoporotic fracture or be hospitalized for stroke during nearly 4 decades of follow-up when compared with those not prescribed HT, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Pellet hormone therapy, a solid custom-compounded bioidentical estrogen therapy that is inserted under the skin, may be less safe than FDA-approved HT therapies for postmenopausal women, according to findings presented at the North American Menopause Society annual meeting.

Hormone therapy may slow the development of diabetes among postmenopausal women due to its effects on certain metabolites, according to findings presented at the North American Menopause Society annual meeting.

Estradiol levels among early and late postmenopausal women taking hormone therapy are influenced by several clinical and lifestyle factors, including BMI, surgical menopause, smoking, alcohol use and antifungal medication use, according to findings presented at the North American Menopause Society annual meeting.